Ondansetron and Central nervous system lesion - a phase IV clinical study of FDA data

Summary:

Central nervous system lesion is reported as a side effect among people who take Ondansetron (ondansetron), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Gilenya, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Central nervous system lesion when taking Ondansetron. It is created by eHealthMe based on reports of 122,217 people who have side effects when taking Ondansetron from the FDA, and is updated regularly.

What is Ondansetron?

Ondansetron has active ingredients of ondansetron. It is often used in nausea. eHealthMe is studying from 122,738 Ondansetron users. Check the latest studies of Ondansetron.

What is Central nervous system lesion?

Central nervous system lesion (an abnormality in tissue of brain or spinal cord) is found to be associated with 780 drugs and 823 conditions by eHealthMe. Check the latest studies of Central nervous system lesion.

On Jul, 06, 2026

122,217 people reported to have side effects when taking Ondansetron.
Among them, 90 people (0.07%) have Central nervous system lesion.

Could Ondansetron cause Central nervous system lesion?

Among these 90 people:

How long have people been on Ondansetron when they have Central nervous system lesion? *

What is the gender of people who have Central nervous system lesion when taking Ondansetron? *

female: 70.93 %
male: 29.07 %

What is the age of people who have Central nervous system lesion when taking Ondansetron? *

What are other drugs people take besides Ondansetron? *

What are other side effects people have besides Central nervous system lesion? *

Fatigue (feeling of tiredness): 35 people, 38.89%
Pain: 34 people, 37.78%
Weakness: 28 people, 31.11%
Depression: 26 people, 28.89%
Fever: 23 people, 25.56%
Fall: 22 people, 24.44%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 21 people, 23.33%
Dyspnea (difficult or laboured breathing): 21 people, 23.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 20 people, 22.22%
Stress And Anxiety: 19 people, 21.11%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 23 people, 25.56%
Pain: 14 people, 15.56%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 11 people, 12.22%
Metastases To Bone (cancer spreads to bone): 10 people, 11.11%
Breast Cancer: 9 people, 10.00%
Gait Disturbance: 6 people, 6.67%
Pain In Jaw: 6 people, 6.67%
Constipation: 6 people, 6.67%
Multiple Myeloma (cancer of the plasma cells): 6 people, 6.67%
Sleep Disorder: 5 people, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Ondansetron and have Central nervous system lesion?

- Check whether Central nervous system lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ondansetron:

Ondansetron (122,738 reports)

Browse all side effects of Ondansetron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Central nervous system lesion:

Central nervous system lesion (780 drugs)

Browse all the conditions that are associated with Central nervous system lesion:

Central nervous system lesion (823 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron (the active ingredients of Ondansetron) and Ondansetron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.